Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025 ...
CHICAGO, IL, USA I 04, 2025 I COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback